Mutations of FGFR2 are present in 12% of endometrial carcinomas [91], and approximately 10% of gastric cancer cases are associated with amplification and/or mutation of FGFR2 [92]; moreover, the degree of amplification is closely related to prognosis. The gene discussed is FGFR2; the disease is endometrial carcinoma.